A5072444138- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Immune cells in cancer
- Inflammatory Biomarkers in Disease Prognosis
- Genomics and Phylogenetic Studies
- Cancer-related molecular mechanisms research
- Lung Cancer Treatments and Mutations
- Pancreatic and Hepatic Oncology Research
- Biomedical Text Mining and Ontologies
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Cancer Cells and Metastasis
- Cancer, Lipids, and Metabolism
- Autophagy in Disease and Therapy
- HER2/EGFR in Cancer Research
- Nutrition, Genetics, and Disease
- Natural product bioactivities and synthesis
- Gastrointestinal Tumor Research and Treatment
- Molecular Biology Techniques and Applications
- Esophageal Cancer Research and Treatment
- Neuroblastoma Research and Treatments
- Microtubule and mitosis dynamics
- Cell Adhesion Molecules Research
- Sesquiterpenes and Asteraceae Studies
Jiangsu Cancer Hospital
2021-2025
Nanjing Medical University
2021-2025
Southern Medical University
2024
Background Hepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer. The lack prognosis indicators one challenges in HCC. In this study, we investigated combination tertiary lymphoid structure (TLS) and several systemic inflammation parameters as a indicator for Materials Methods We retrospectively recruited 126 postoperative patients with paraffin section was collected TLS density assessment. addition, from peripheral blood samples. evaluated prognostic...
Background PD-1 inhibitors have been routinely used in the treatment of advanced non-small cell lung cancer (NSCLC), and demonstrated to significantly improve survivorship when combining with other conventional therapies, such as chemotherapy anti-angiogenesis therapy. PD-L1 is most commonly biomarker select benefiting groups, while not all patients high expression benefit from immunotherapy. Therefore, identifying prognostic predictive biomarkers, including peripheral blood indexes,...
Epidermal growth factor receptor (EGFR) sensitive mutation is one of the effective targets targeted therapy for non-small cell lung cancer (NSCLC). However, due to difficulty obtaining some primary tissues and economic factors in underdeveloped areas, patients cannot undergo traditional genetic testing. The aim this study establish a machine learning (ML) model using non-invasive peripheral blood markers explore biomarkers closely related EGFR status NSCLC evaluate their potential prognostic...
The dysfunction of natural killer (NK) cells has been increasingly reported in malignancies, especially solid tumours. Mesenchymal stem (MSCs) exhibit pleiotropic functions that include mediating immune cell exhaustion which is implicated cancer progression. However, the association MSCs derived from gastric (gastric mesenchymal cells: GCMSCs) with NK remains poorly understood. In this study, we demonstrated GCMSCs effectively contributed to through release soluble factors. Furthermore,...
Some research found that elevated plasma cell-free DNA (cfDNA) concentrations and poor prognosis are associated in non-small cell lung cancer (NSCLC). However, more studies need to be carried out verify this conclusion. Therefore, study investigated the relationship between cfDNA concentration treatment outcomes including patients with advanced NSCLC.We retrospectively collected medical records data from 160 NSCLC. Progression-free survival (PFS) were calculated using Kaplan-Meier method...
Lung cancer is among the major diseases threatening human health. Although immune response plays an important role in tumor development, its exact mechanisms are unclear.Here, we used CIBERSORT and ESTIMATE algorithms to determine proportion of tumor-infiltrating cells (TICs) as well number mesenchymal components from data 474 lung patients Gene Expression Omnibus database. And The Cancer Genome Atlas database (TCGA) for validation.We observed that immune, stromal, assessment scores were...
Gastric cancer (GC) is the third leading cause of cancer-associated deaths worldwide. Stromal cells, especially mesenchymal stem cells (MSCs), play significant roles in development therapy resistance depending on their paracrine function. The PD-1/PD-L1 crosstalk between and immune has been well studied. Emerging evidence suggests that PD-L1 also contributes to tumor therapy. Cell survival apoptosis were assessed using CCK-8, colony formation, flow cytometry assays. Protein alterations...
Programmed Cell Death-1/ Death-ligand 1 (PD-1 / PD-L1) inhibitor therapies targeting immunocytes induce persistent tumor remission in various cancers. However, the appropriate biomarkers for therapeutic efficacy of PD-L1 and PD-1 blockade remain elusive.For a comprehensive analysis peri-treatment lymphocyte differentiation, current study, we enrolled 146 non-small cell lung cancer patients who received α-PD-1 exploring peripheral blood differentiation pattern at baseline post-treatment...
Abstract Cancer stem cells (CSCs) are believed to be crucial in the initiation, progression, and recurrence of cancer. CSCs also known more resistant cancer treatments. However, interaction between immune microenvironment is complex not fully understood. In current study we used single cell RNA sequence (scRNA-Seq, public dataset) technology identify characteristic CSCs. We found that lung adenocarcinoma population highly inflammatory remodels tumor by secreting factors, specifically acute...
For advanced gastric cancer (GC) patients who fail first-line treatment, chemotherapy alone is of limited benefit. Ramucirumab combined with paclitaxel and apatinib docetaxel provided clinical benefit in previous studies, but the feasibility other agents remains unknown. The aim present study was to evaluate efficacy safety as a second-line treatment for GC.Patients aged 18-75 years histologically or cytologically confirmed metastatic GC gastroesophageal junction adenocarcinoma that had...
BackgroundMalignant tumours, particularly non-small cell lung cancer (NSCLC), pose a significant threat to human health due their prevalence and lethality. Treatment methods for NSCLC vary greatly among individuals, making it crucial identify predictive markers. Moreover, during tumour initiation progression, cells can release signaling molecules induce polarization of macrophages towards more friendly M2 phenotype, which promote growth, metastasis, drug resistance.MethodsWe employed...
Despite the recognized therapeutic potential of programmed cell death protein 1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors in advanced esophageal squamous carcinoma (ESCC), their role neoadjuvant therapy and reliable efficacy biomarkers remain elusive.
Immunotherapy deeply changed the treatment paradigm of advanced non-small cell lung cancer (NSCLC) in past years. However, objective response rate (ORR) after immunotherapy is about 20-30% NSCLC patients. Therefore, identification predictive biomarkers crucial for selecting patients with who would most benefit from programmed death receptor protein 1 (PD-1) inhibitor-based immunotherapy.We retrospectively collected medical records and thioredoxin reductase (TrxR) data 90 a received PD-1...
Lung cancer is the leading cause of cancer-related death, which non-small cell lung (NSCLC) most common type. Immune checkpoint inhibitors (ICIs) have now become one main treatments for advanced NSCLC. This paper retrospectively investigated effect peripheral blood inflammatory indexes on efficacy immunotherapy and survival patients with cancer, in order to find strategies guide NSCLC.Patients who were hospitalized The Affiliated Cancer Hospital Nanjing Medical University from October 2018...
Interpreting genes of interest is essential for identifying molecular mechanisms, but acquiring such information typically involves tedious manual retrieval. To streamline this process, the fanyi package offers tools to retrieve gene from sources like National Center Biotechnology Information (NCBI), significantly enhancing accessibility. Additionally, understanding latest research advancements and sharing achievements are crucial junior researchers. However, language barriers often restrict...
2536 Background: Combinations of EGFR inhibitors and other targeted agents in patients whose tumors have mutations and/or previously responded to but then progressed may provide synergy help overcome resistance. Methods: Patients with advanced cancers received daily erlotinib at an oral dose 150 mg or 100-150 either bortezomib 1mg/m2 – 1.3mg/m2 IV days 1,4,8 11, cetuximab 125mg/m2 250mg/m2 weekly, dasatinib 50-70mg bid. An umbrella Phase I 3+3 trial was designed determine MTD. At MTD,...
Abstract Understanding the latest research advancements and sharing one’s own achievements is extremely important for young researchers. However, language barriers restrict absorption of knowledge career development. To address these issues, we have developed fanyi package, which utilizes AI-driven online translation services to accurately translate between multiple languages. This helps researchers rapidly capture information, promotes preservation a multilingual environment, ultimately...
Wen, S.; Lou, Y.; Liu, Wu, H.; Wang, Z.; K.; Li, Z. Author Information